retatrutide sleep apnea Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% retatrutide clinical study Eli Lilly

Finally, although most of the evidence of a potential benefit of GLP-1 RAs in HF originates from CVOTs in type 2 diabetes, it may likely be in the weight management setting that the drug class could be of the highest clinical value, particularly in people with HFpEF

Second, as the main analysis, we used a per-protocol approach to estimate the increased risk of SIS in GLP-1RA vs SGLT-2i users

A prospective case series study found that GLP-1RAs, such as liraglutide and exenatide, reduced the population of cutaneous T cells and the expression of IL-17 in skin lesions

Management of acute kidney disease in type 2 diabetes: the potential role of GLP-1 RAs and SGLT2-Is

In the cardiovascular system, atherosclerosis becomes apparent as the invisible killer. Atherosclerosis causes cerebral ischemia, or angina pectoris, with the development of atherosclerotic plaques

Media Influence: Media, including advertisements, TV shows, and movies, often promote fair-skinned individuals as the epitome of beauty